SCHEMBL1574440

SCHEMBL1574440

CCN(CC)C1CN(C(=O)Nc2cccc3ccccc23)C1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 14/20 0.60
ALDH1A1 P00352 8/20 0.60
HSD17B10 Q99714 7/20 0.60
POLB P06746 2/20 0.58
TSHR P16473 1/20 0.54
LMNA P02545 2/20 0.52
USP2 O75604 1/20 0.52
ALOX15 P16050 1/20 0.52
MAPK1 P28482 1/20 0.52
HPGD P15428 1/20 0.51
TAAR1 Q96RJ0 1/20 0.51
KMT2A Q03164 2/20 0.49
PKM P14618 1/20 0.48
MEN1 O00255 1/20 0.48
NPC1 O15118 1/20 0.48
EPHX1 P07099 1/20 0.47
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
HRH4 Q9H3N8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575080 0.90 KDM4E (0.58) KDM4EALDH1A1HSD17B10POLBTSHR
SCHEMBL1574969 0.87 KDM4E (0.54) KDM4EALDH1A1HSD17B10POLBTSHR
SCHEMBL1575912 0.86 KDM4E (0.53) KDM4EALDH1A1HSD17B10POLBTSHR
SCHEMBL1574559 0.86 KDM4E (0.56) KDM4EALDH1A1HSD17B10POLBTSHR
SCHEMBL1575173 0.86 KDM4E (0.61) KDM4EALDH1A1HSD17B10POLBTSHR
SCHEMBL1574669 0.83 GAA (0.51) KDM4EALDH1A1LMNAMAPK1HPGD
SCHEMBL1574850 0.83 TAAR1 (0.54) KDM4EPOLBTSHRLMNATAAR1
SCHEMBL1575325 0.82 KDM4E (0.57) KDM4EALDH1A1HSD17B10POLBTSHR
SCHEMBL1574831 0.82 KDM4E (0.64) KDM4EKMT2APKMNPC1
SCHEMBL1574839 0.82 GAA (0.55) KDM4EALDH1A1POLBTSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB KDM4E 516/4885ALDH1A1 1445/4885HSD17B10 1325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.